Literature DB >> 27346916

Secondary osteoporosis.

Angela Sheu1, Terry Diamond1.   

Abstract

Secondary osteoporosis is less common than primary osteoporosis. It may be suspected in patients who present with a fragility fracture despite having no risk factors for osteoporosis. In addition, secondary osteoporosis should be considered if the bone density Z-score is -2.5 or less. Consider the fracture site and presence of other clinical clues to guide investigations for an underlying cause. The tests to use are those that are indicated for the suspected cause. Baseline investigations include tests for bone and mineral metabolism (calcium, phosphate, alkaline phosphatase, 25-hydroxyvitamin D, parathyroid hormone), liver and kidney function, full blood count and thyroid-stimulating hormone. More detailed testing may be required in patients with severe osteoporosis.

Entities:  

Keywords:  Z-score; biopsy of bone; bone density; fracture of bone; osteoporosis

Year:  2016        PMID: 27346916      PMCID: PMC4919174          DOI: 10.18773/austprescr.2016.038

Source DB:  PubMed          Journal:  Aust Prescr        ISSN: 0312-8008


  9 in total

Review 1.  Secondary causes of osteoporosis.

Authors:  Lorraine A Fitzpatrick
Journal:  Mayo Clin Proc       Date:  2002-05       Impact factor: 7.616

Review 2.  Secondary osteoporosis - an endocrinological approach focusing on underlying mechanisms.

Authors:  A Polymeris; K Michalakis; V Sarantopoulou
Journal:  Endocr Regul       Date:  2013-07

Review 3.  Approach to the patient with secondary osteoporosis.

Authors:  Lorenz C Hofbauer; Christine Hamann; Peter R Ebeling
Journal:  Eur J Endocrinol       Date:  2010-03-15       Impact factor: 6.664

Review 4.  Osteoporosis in young adults: pathophysiology, diagnosis, and management.

Authors:  S Ferrari; M L Bianchi; J A Eisman; A J Foldes; S Adami; D A Wahl; J J Stepan; M-C de Vernejoul; J-M Kaufman
Journal:  Osteoporos Int       Date:  2012-06-09       Impact factor: 4.507

Review 5.  Laboratory testing for secondary osteoporosis evaluation.

Authors:  Robert A Adler
Journal:  Clin Biochem       Date:  2012-02-04       Impact factor: 3.281

6.  Transiliac bone biopsy in osteoporosis: frequency, indications, consequences and complications. An evaluation of 99 consecutive cases over a period of 14 years.

Authors:  P H Kann; A Pfützner; G Delling; G Schulz; S Meyer
Journal:  Clin Rheumatol       Date:  2005-05-25       Impact factor: 2.980

7.  Search for hidden secondary causes in postmenopausal women with osteoporosis.

Authors:  Dacia Cerdá Gabaroi; Pilar Peris; Ana Monegal; Carolina Albaladejo; Ma Angels Martínez; Africa Muxí; Ma Jesús Martínez de Osaba; Xavier Surís; Núria Guañabens
Journal:  Menopause       Date:  2010 Jan-Feb       Impact factor: 2.953

8.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women.

Authors:  Cara Tannenbaum; Julie Clark; Kevin Schwartzman; Sylvan Wallenstein; Robert Lapinski; Diane Meier; Marjorie Luckey
Journal:  J Clin Endocrinol Metab       Date:  2002-10       Impact factor: 5.958

Review 9.  Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis.

Authors:  Jehoon Lee; Samuel Vasikaran
Journal:  Ann Lab Med       Date:  2012-02-23       Impact factor: 3.464

  9 in total
  9 in total

1.  Assessment of osteoporotic alterations in type 2 diabetes: a retrospective study.

Authors:  Luciana Munhoz; Arthur R G Cortes; Emiko S Arita
Journal:  Dentomaxillofac Radiol       Date:  2017-03-28       Impact factor: 2.419

Review 2.  Dual-energy X-ray absorptiometry bone densitometry in pediatrics: a practical review and update.

Authors:  Hedieh Khalatbari; Larry A Binkovitz; Marguerite T Parisi
Journal:  Pediatr Radiol       Date:  2020-08-28

3.  Improved fracture prediction using different fracture risk assessment tool adjustments in HIV-infected women.

Authors:  Jingyan Yang; Anjali Sharma; Qiuhu Shi; Kathryn Anastos; Mardge H Cohen; Elizabeth T Golub; Deborah Gustafson; Daniel Merenstein; Wendy J Mack; Phyllis C Tien; Jeri W Nieves; Michael T Yin
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

4.  Thyroid-stimulating hormone (TSH) is associated with 30-day mortality in hip fracture patients.

Authors:  Etienne Rapacki; Jes B Lauritzen; Christian M Madsen; Henrik L Jørgensen; Debbie Norring-Agerskov
Journal:  Eur J Trauma Emerg Surg       Date:  2019-11-06       Impact factor: 3.693

5.  ACY‑1215, a HDAC6 inhibitor, decreases the dexamethasone‑induced suppression of osteogenesis in MC3T3‑E1 cells.

Authors:  Na Wang; Hua Wang; Jianming Chen; Fubin Wang; Shuaiyi Wang; Qiang Zhou; Jichong Ying; Shanzhao Huang; Pu Wang; Fangfang Yuan
Journal:  Mol Med Rep       Date:  2020-07-09       Impact factor: 2.952

6.  Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review.

Authors:  Michelle Gates; Jennifer Pillay; Guylène Thériault; Heather Limburg; Roland Grad; Scott Klarenbach; Christina Korownyk; Donna Reynolds; John J Riva; Brett D Thombs; Gregory A Kline; William D Leslie; Susan Courage; Ben Vandermeer; Robin Featherstone; Lisa Hartling
Journal:  Syst Rev       Date:  2019-08-23

7.  Prevalence and risk factors for osteoporotic fracture among adults with comorbidities in Al-Ahsaa, Saudi Arabia.

Authors:  Naif M Al Hamam; Ghusoon F Al-Moaibed; Emad H Alfayez; Eman H Alfayez; Mohammed Saud Al-Mubaddil; Narjes Ali Alramadhan
Journal:  J Family Med Prim Care       Date:  2020-02-28

8.  The Relation Between Calcaneus Stiffness Index as a Measure of Bone Density and Body Mass Index in an Egyptian Cohort.

Authors:  Khalid Ali; Salma Ms El Said; Nermien N Adly; Samia A Abdul-Rahman
Journal:  J Multidiscip Healthc       Date:  2019-12-31

Review 9.  Use of in vitro bone models to screen for altered bone metabolism, osteopathies, and fracture healing: challenges of complex models.

Authors:  Sabrina Ehnert; Helen Rinderknecht; Romina H Aspera-Werz; Victor Häussling; Andreas K Nussler
Journal:  Arch Toxicol       Date:  2020-09-10       Impact factor: 5.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.